- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05936138
A Study of LY3502970 in Participants With Normal and Impaired Renal Function
April 22, 2024 updated by: Eli Lilly and Company
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function.
The safety and tolerability of LY3502970 will also be evaluated in these participants.
The study will last up to 6 weeks including screening period.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@lilly.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33147
- Advanced Pharma CR, LLC
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami
-
Principal Investigator:
- Alexander Prezioso
-
Contact:
- Phone Number: 305-817-2900
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
Principal Investigator:
- Thomas C Marbury
-
Contact:
- Phone Number: 407-475-0227
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Alliance for Multispecialty Research, LLC
-
Principal Investigator:
- William B. Smith
-
Contact:
- Phone Number: +1 865-305-9100 x2246
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Have a body mass index within the range 18.5 to 42.0 kilograms per meter squared (kg/m²), inclusive.
- Men and women who agree to use highly effective or effective methods of contraception may participate in this trial.
Participants with Normal Renal Function:
- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function. Have estimated glomerular filtration rate (eGFR) of greater than or equal to 90 milliliter per minute (mL/min)
Participants with Renal Impairment:
- Severe renal impairment: Have eGFR of 15 to 29 mL/min and not requiring hemodialysis.
- ESRD: Participants who have been on a stable hemodialysis schedule for at least 3 months prior to planned dosing.
Exclusion Criteria:
- Have a current, functioning organ transplant. Non-functional renal allografts may be allowed.
- Regularly use known drugs of abuse or show positive findings on urinary drug screen that are not otherwise explained by permitted concomitant medications.
- Have known allergies to LY3502970, related compounds, or any components of the formulation, or history of severe atopy.
- Are lactating, pregnant, or intend to become pregnant, or to breastfeed during the study.
- Have a history or presence of chronic or acute pancreatitis
Participants with Renal Impairment:
- Have hemoglobin <8.5 g/dL.
- Participants with Type 2 Diabetes Mellitus if they have taken any Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA) or a Dipeptidyl Peptidase 4 (DPP4) inhibitor in the past 6 weeks or 5 half-lives prior to dosing, whichever is longer, prior to dosing on Day 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY3502970 (Severe Renal Impairment)
LY3502970 administered orally to participants with severe renal impairment
|
Administered orally.
|
Experimental: LY3502970 (End-Stage Renal Disease)
LY3502970 administered orally to participants with end-stage renal disease (ESRD)
|
Administered orally.
|
Experimental: LY3502970 (Control)
LY3502970 administered orally to participants with normal renal function
|
Administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3502970
Time Frame: Predose up to 12 days postdose
|
PK: (AUC0-∞) of LY3502970
|
Predose up to 12 days postdose
|
PK: Area under the concentration versus time curve from time zero to last time point (AUC0-tlast) of LY3502970
Time Frame: Predose up to 12 days postdose
|
PK: AUC0-tlast of LY3502970
|
Predose up to 12 days postdose
|
PK: Maximum observed concentration (Cmax) of LY3502970
Time Frame: Predose up to 12 days postdose
|
PK: Cmax of LY3502970
|
Predose up to 12 days postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2023
Primary Completion (Actual)
April 11, 2024
Study Completion (Actual)
April 11, 2024
Study Registration Dates
First Submitted
June 30, 2023
First Submitted That Met QC Criteria
June 30, 2023
First Posted (Actual)
July 7, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18633
- J2A-MC-GZPC (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on LY3502970
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedHealthy | ObeseUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Germany
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Eli Lilly and CompanyRecruitingType 2 DiabetesUnited States, Mexico, Japan, India, Puerto Rico, China
-
Eli Lilly and CompanyActive, not recruiting